clinical trial · NCT07165951
Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.·phase3·recruiting·n = 566
Metastatic Pancreatic Ductal AdenocarcinomaTQB2868 InjectionAnlotinib Hydrochloride CapsulesGemcitabine Hydrochloride InjectionPaclitaxel for InjectionTQB2868 Placebo
brief summary
This study adopts a randomized, open label, placebo-controlled, multicenter trial design. OS was the primary endpoint, and eligible subjects were randomly divided into 1:1 groups and received TQB2868 injection and anlotinib hydrochloride capsules combined with chemotherapy, compared to placebo combined with chemotherapy.
started
Dec 2, 2025
primary completion
May 1, 2028
completion
Dec 1, 2028
last updated
May 29, 2026
official title
A Randomized, Double-blind, Parallel-controlled, Multicenter Phase III Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules to Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol